BiotechTube
STA Pharmaceutical

STA Pharmaceutical

2359.HK / 603259.SH
San Diego, United States· Est.
sta.wuxiapptec.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $113M

Overview

WuXi STA operates as a leading global CDMO, offering a comprehensive 'One Stop Solution' for drug substance, drug product, analytical, and regulatory services. Its strategy leverages a vast global footprint, deep scientific expertise, and specialized technology platforms to serve a broad client base, from virtual biotechs to large pharma. The company's integration within the WuXi AppTec ecosystem provides unparalleled scale and a full continuum of R&D and manufacturing services, positioning it as a critical enabler of the global biopharmaceutical industry.

Generic Drugs

Technology Platform

Fully integrated 'One Stop Solution' CDMO platform encompassing Drug Substance (API), Drug Product (Oral, Parenteral, LNP), Analytical Development, and Regulatory CMC services for small molecules and complex modalities.

Funding History

3
Total raised:$113M
Series C$60M
Series B$38M
Series A$15M

Opportunities

The company is leveraged to powerful secular trends: increased biopharma outsourcing, the rise of capital-efficient virtual biotechs, and the growth of complex modalities like mRNA and oligonucleotides.
Its 'Global Dual Sourcing' strategy, with substantial capacity in both China and the West, uniquely positions it to offer clients supply chain resilience and geographic optionality.

Risk Factors

Geopolitical tensions between the US/West and China pose an existential threat, potentially disrupting trade, client sentiment, and operations.
Execution risk in rapid global expansion and maintaining flawless quality/compliance across all sites is critical.
Intense competition in the CDMO space could pressure pricing and margins.

Competitive Landscape

Competes with large global CDMOs (Lonza, Catalent) and specialized firms. Key advantages include its unparalleled scale and integration within the WuXi AppTec ecosystem, a cost-competitive and high-quality manufacturing base in China, and a strategic Western footprint that mitigates client supply chain concerns.

More companies in Small Molecule Drugs →More companies in United States →